Floatz logo

Plerixafor

Waldenström Macroglobulinemia

Case Comprehensive Cancer CenterSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

60 Active assets in the Waldenström Macroglobulinemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BBB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
PREDNISONE TABLETS
BeOne Medicines
Phase 2BBB
Inno-206
BeOne Medicines
Phase 2BBB

View all 50 →

Same molecule, other indications

Plerixafor is also rated in:

Fanconi anemiaDormant
BB
Indicative ·
70 / 100
View asset →
Hodgkins lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
non-Hodgkin lymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →